Agios Pharmaceuticals Statistics
Share Statistics
Agios Pharmaceuticals has 57.92M
shares outstanding. The number of shares has increased by 0.92%
in one year.
| Shares Outstanding | 57.92M |
| Shares Change (YoY) | 0.92% |
| Shares Change (QoQ) | 0.47% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 68 |
| FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 4.16M, so 7.18% of the outstanding
shares have been sold short.
| Short Interest | 4.16M |
| Short % of Shares Out | 7.18% |
| Short % of Float | 7.23% |
| Short Ratio (days to cover) | 8.18 |
Valuation Ratios
The PE ratio is 2.77 and the forward
PE ratio is -4.65.
Agios Pharmaceuticals's PEG ratio is
-0.01.
| PE Ratio | 2.77 |
| Forward PE | -4.65 |
| PS Ratio | 51.15 |
| Forward PS | 1.8 |
| PB Ratio | 1.21 |
| P/FCF Ratio | -4.77 |
| PEG Ratio | -0.01 |
Financial Ratio HistoryEnterprise Valuation
Agios Pharmaceuticals has an Enterprise Value (EV) of 1.85B.
| EV / Sales | 50.62 |
| EV / EBITDA | -4.34 |
| EV / EBIT | -4.74 |
| EV / FCF | -4.72 |
Financial Position
The company has a current ratio of 11.9,
with a Debt / Equity ratio of 0.04.
| Current Ratio | 11.9 |
| Quick Ratio | 11.56 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | -0.13 |
| Debt / FCF | -0.15 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is 43.72% and Return on Invested Capital is -24.99%.
| Return on Equity | 43.72% |
| Return on Assets | 40.51% |
| Return on Invested Capital | -24.99% |
| Revenue Per Employee | $75,098.77 |
| Profits Per Employee | $1,386,265.43 |
| Employee Count | 486 |
| Asset Turnover | 0.02 |
| Inventory Turnover | 0.15 |
Taxes
| Income Tax | 44.24M |
| Effective Tax Rate | 6.16% |
Stock Price Statistics
The stock price has increased by -15.08% in the
last 52 weeks. The beta is 0.77, so Agios Pharmaceuticals's
price volatility has been higher than the market average.
| Beta | 0.77 |
| 52-Week Price Change | -15.08% |
| 50-Day Moving Average | 28.94 |
| 200-Day Moving Average | 38.8 |
| Relative Strength Index (RSI) | 64.46 |
| Average Volume (20 Days) | 621,750 |
Income Statement
In the last 12 months, Agios Pharmaceuticals had revenue of 36.5M
and earned 673.73M
in profits. Earnings per share was 11.86.
| Revenue | 36.5M |
| Gross Profit | 32.33M |
| Operating Income | -425.74M |
| Net Income | 673.73M |
| EBITDA | -425.74M |
| EBIT | -425.74M |
| Earnings Per Share (EPS) | 11.86 |
Full Income StatementBalance Sheet
The company has 76.25M in cash and 56.99M in
debt, giving a net cash position of 19.26M.
| Cash & Cash Equivalents | 76.25M |
| Total Debt | 56.99M |
| Net Cash | 19.26M |
| Retained Earnings | -148.92M |
| Total Assets | 1.56B |
| Working Capital | 916.25M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -389.84M
and capital expenditures -1.69M, giving a free cash flow of -391.53M.
| Operating Cash Flow | -389.84M |
| Capital Expenditures | -1.69M |
| Free Cash Flow | -391.53M |
| FCF Per Share | -6.89 |
Full Cash Flow StatementMargins
Gross margin is 88.59%, with operating and profit margins of -1166.47% and 1845.92%.
| Gross Margin | 88.59% |
| Operating Margin | -1166.47% |
| Pretax Margin | 1967.15% |
| Profit Margin | 1845.92% |
| EBITDA Margin | -1166.47% |
| EBIT Margin | -1166.47% |
| FCF Margin | -1072.73% |
